Stephens Inc. AR Sells 228 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Stephens Inc. AR reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,689 shares of the medical research company’s stock after selling 228 shares during the quarter. Stephens Inc. AR’s holdings in Charles River Laboratories International were worth $332,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRL. Price T Rowe Associates Inc. MD lifted its stake in shares of Charles River Laboratories International by 399.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,104,292 shares of the medical research company’s stock valued at $236,285,000 after purchasing an additional 883,029 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Charles River Laboratories International by 1,739.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 645,263 shares of the medical research company’s stock valued at $138,065,000 after purchasing an additional 610,182 shares during the period. Clearbridge Investments LLC lifted its stake in shares of Charles River Laboratories International by 28.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock valued at $388,739,000 after purchasing an additional 301,159 shares during the period. First Republic Investment Management Inc. lifted its stake in shares of Charles River Laboratories International by 3,792.3% in the 1st quarter. First Republic Investment Management Inc. now owns 156,277 shares of the medical research company’s stock valued at $44,378,000 after purchasing an additional 152,262 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in shares of Charles River Laboratories International by 15.3% in the 2nd quarter. Mackenzie Financial Corp now owns 987,234 shares of the medical research company’s stock valued at $211,238,000 after purchasing an additional 131,020 shares during the period. Hedge funds and other institutional investors own 97.80% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $252.55 on Tuesday. The stock has a 50-day simple moving average of $226.72 and a two-hundred day simple moving average of $218.60. Charles River Laboratories International, Inc. has a 52-week low of $181.36 and a 52-week high of $349.84. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40. The firm has a market capitalization of $12.85 billion, a PE ratio of 29.75, a P/E/G ratio of 1.53 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The medical research company reported $2.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.12. Charles River Laboratories International had a return on equity of 20.93% and a net margin of 11.54%. The business had revenue of $989.16 million during the quarter, compared to analyst estimates of $978.65 million. Analysts forecast that Charles River Laboratories International, Inc. will post 10.89 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. StockNews.com initiated coverage on Charles River Laboratories International in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Credit Suisse Group lowered their price objective on Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd. Morgan Stanley lowered their price objective on Charles River Laboratories International from $250.00 to $241.00 and set an “equal weight” rating for the company in a research note on Thursday, November 3rd. William Blair reiterated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, November 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, November 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $297.38.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 534 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $216.36, for a total value of $115,536.24. Following the completion of the transaction, the executive vice president now owns 20,232 shares of the company’s stock, valued at $4,377,395.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Joseph W. Laplume sold 6,409 shares of the company’s stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $224.25, for a total value of $1,437,218.25. Following the completion of the transaction, the executive vice president now owns 20,232 shares of the company’s stock, valued at $4,537,026. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 534 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $216.36, for a total value of $115,536.24. Following the completion of the transaction, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at approximately $4,377,395.52. The disclosure for this sale can be found here. Insiders sold a total of 10,077 shares of company stock valued at $2,334,821 over the last 90 days. Company insiders own 1.10% of the company’s stock.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.